Novocure Stock Beta

NVCR Stock

USD 11.76 0.44 3.89%

Fundamental analysis of Novocure allows traders to better anticipate movements in Novocure's stock price by examining its financial health and performance throughout various phases of its business cycle.

Short Long Term Debt Total Total Assets

Build AI portfolio with Novocure Stock

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Novocure Company Beta Analysis

Novocure's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.

Beta

Covariance

Variance

More About Beta | All Equity Analysis

Current Novocure Beta

0.61

Most of Novocure's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novocure is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Novocure Beta Driver Correlations

Understanding the fundamental principles of building solid financial models for Novocure is extremely important. It helps to project a fair market value of Novocure Stock properly, considering its historical fundamentals such as Beta. Since Novocure's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Novocure's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Novocure's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Net Receivables	Short Term Investments	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Property Plant Equipment	Long Term Investments	Current Deferred Revenue	Long Term Debt Total	Capital Surpluse	Net Invested Capital	Net Working Capital
Total Assets		0.92	0.96	0.89	-0.8	0.89	0.83	0.92	0.94	0.93	0.83	1.0	0.43	0.77	0.79	0.94	0.92	0.98	0.99	0.87
Total Stockholder Equity	0.92		0.96	0.75	-0.59	0.76	0.8	0.84	0.87	0.81	0.69	0.93	0.27	0.6	0.6	0.87	0.83	0.86	0.92	0.89
Net Tangible Assets	0.96	0.96		0.78	-0.67	0.8	0.74	0.83	0.87	0.83	0.7	0.96	0.37	0.64	0.65	0.85	0.85	0.93	0.94	0.81
Net Debt	0.89	0.75	0.78		-0.92	0.97	0.66	0.84	0.98	0.98	0.85	0.89	0.71	0.75	0.78	0.87	0.97	0.91	0.92	0.78
Retained Earnings	-0.8	-0.59	-0.67	-0.92		-0.93	-0.53	-0.78	-0.86	-0.92	-0.89	-0.78	-0.76	-0.73	-0.88	-0.8	-0.86	-0.85	-0.79	-0.6
Accounts Payable	0.89	0.76	0.8	0.97	-0.93		0.62	0.82	0.96	0.99	0.86	0.88	0.73	0.73	0.74	0.86	0.98	0.92	0.92	0.76
Long Term Debt	0.83	0.8	0.74	0.66	-0.53	0.62		0.81	0.73	0.69	0.66	0.84	-0.04	0.69	0.62	0.85	0.67	0.72	0.8	0.93
Net Receivables	0.92	0.84	0.83	0.84	-0.78	0.82	0.81		0.86	0.87	0.89	0.93	0.37	0.84	0.87	0.97	0.82	0.9	0.9	0.84
Short Term Investments	0.94	0.87	0.87	0.98	-0.86	0.96	0.73	0.86		0.98	0.83	0.94	0.62	0.73	0.73	0.9	0.98	0.93	0.97	0.86
Total Liab	0.93	0.81	0.83	0.98	-0.92	0.99	0.69	0.87	0.98		0.89	0.92	0.68	0.75	0.78	0.91	0.99	0.94	0.95	0.82
Short Long Term Debt	0.83	0.69	0.7	0.85	-0.89	0.86	0.66	0.89	0.83	0.89		0.82	0.54	0.74	0.88	0.93	0.83	0.84	0.82	0.74
Total Current Assets	1.0	0.93	0.96	0.89	-0.78	0.88	0.84	0.93	0.94	0.92	0.82		0.42	0.77	0.78	0.94	0.92	0.97	0.99	0.88
Short Term Debt	0.43	0.27	0.37	0.71	-0.76	0.73	-0.04	0.37	0.62	0.68	0.54	0.42		0.39	0.48	0.37	0.68	0.55	0.49	0.17
Property Plant Equipment	0.77	0.6	0.64	0.75	-0.73	0.73	0.69	0.84	0.73	0.75	0.74	0.77	0.39		0.78	0.77	0.71	0.74	0.73	0.64
Long Term Investments	0.79	0.6	0.65	0.78	-0.88	0.74	0.62	0.87	0.73	0.78	0.88	0.78	0.48	0.78		0.83	0.69	0.79	0.73	0.59
Current Deferred Revenue	0.94	0.87	0.85	0.87	-0.8	0.86	0.85	0.97	0.9	0.91	0.93	0.94	0.37	0.77	0.83		0.88	0.91	0.94	0.92
Long Term Debt Total	0.92	0.83	0.85	0.97	-0.86	0.98	0.67	0.82	0.98	0.99	0.83	0.92	0.68	0.71	0.69	0.88		0.93	0.96	0.82
Capital Surpluse	0.98	0.86	0.93	0.91	-0.85	0.92	0.72	0.9	0.93	0.94	0.84	0.97	0.55	0.74	0.79	0.91	0.93		0.97	0.79
Net Invested Capital	0.99	0.92	0.94	0.92	-0.79	0.92	0.8	0.9	0.97	0.95	0.82	0.99	0.49	0.73	0.73	0.94	0.96	0.97		0.89
Net Working Capital	0.87	0.89	0.81	0.78	-0.6	0.76	0.93	0.84	0.86	0.82	0.74	0.88	0.17	0.64	0.59	0.92	0.82	0.79	0.89

Click cells to compare fundamentals

In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.

Competition

Predict Novocure

In accordance with the recently published financial statements, Novocure has a Beta of 0.608. This is 29.3% lower than that of the Health Care Equipment & Supplies sector and 30.91% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.

Novocure Beta Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Novocure's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Novocure could also be used in its relative valuation, which is a method of valuing Novocure by comparing valuation metrics of similar companies.

Novocure is currently under evaluation in beta category among its peers.

Novocure Current Valuation Drivers

We derive many important indicators used in calculating different scores of Novocure from analyzing Novocure's financial statements. These drivers represent accounts that assess Novocure's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Novocure's important valuation drivers and their relationship over time.

	2020	2021	2022	2023	2024	2025 (projected)
Market Cap	17.5B	7.8B	7.7B	1.6B	1.4B	1.4B
Enterprise Value	17.7B	8.1B	8.1B	1.9B	1.7B	1.7B

Novocure ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Novocure's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Novocure's managers, analysts, and investors.

Environmental

Governance

Social

Novocure Institutional Holders

Institutional Holdings refers to the ownership stake in Novocure that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Novocure's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Novocure's value.

		Shares
Northern Trust Corp	2025-03-31	1.2 M
Baillie Gifford & Co Limited.	2025-03-31	1.1 M
Palo Alto Investors, Llc	2025-03-31	1 M
Goldman Sachs Group Inc	2025-03-31	993.7 K
Quantinno Capital Management Lp	2025-03-31	988.3 K
Charles Schwab Investment Management Inc	2025-03-31	818.8 K
Renaissance Technologies Corp	2025-03-31	768.7 K
Voloridge Investment Management, Llc	2025-03-31	726 K
Nuveen, Llc	2025-03-31	693.8 K
Fmr Inc	2025-03-31	16.5 M
Blackrock Inc	2025-03-31	13 M

As returns on the market increase, Novocure's returns are expected to increase less than the market. However, during the bear market, the loss of holding Novocure is expected to be smaller as well.

Novocure Fundamentals

	Return On Equity	-0.48
	Return On Asset	-0.0864
	Profit Margin	(0.27) %
	Operating Margin	(0.25) %
	Current Valuation	1.05 B
	Shares Outstanding	111.8 M
	Shares Owned By Insiders	9.81 %
	Shares Owned By Institutions	79.13 %
	Number Of Shares Shorted	4.93 M
	Price To Earning	721.15 X
	Price To Book	3.62 X
	Price To Sales	2.01 X
	Revenue	605.22 M
	Gross Profit	482.34 M
	EBITDA	(108.26 M)
	Net Income	(168.63 M)
	Cash And Equivalents	948.52 M
	Cash Per Share	9.06 X
	Total Debt	683.35 M
	Debt To Equity	1.31 %
	Current Ratio	8.08 X
	Book Value Per Share	3.13 X
	Cash Flow From Operations	(26.37 M)
	Short Ratio	3.87 X
	Earnings Per Share	(1.56) X
	Price To Earnings To Growth	(0.47) X
	Target Price	27.19
	Number Of Employees	1.49 K
	Beta	0.61
	Market Capitalization	1.27 B
	Total Asset	1.24 B
	Retained Earnings	(1.15 B)
	Working Capital	350.2 M
	Current Asset	293.9 M
	Current Liabilities	28.63 M
	Net Asset	1.24 B

About Novocure Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Novocure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Novocure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Novocure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Novocure

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Novocure position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Novocure will appreciate offsetting losses from the drop in the long position's value.

Moving together with Novocure Stock

0.66

Cigna Corp

Pair Corr

Moving against Novocure Stock

0.49	EW	Edwards Lifesciences Corp	Pair Corr
0.46	ECOR	Electrocore LLC	Pair Corr
0.43	LH	Laboratory	Pair Corr
0.42	VSEE	VSee Health,	Pair Corr
0.41	VEEV	Veeva Systems Class	Pair Corr

The ability to find closely correlated positions to Novocure could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Novocure when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Novocure - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Novocure to buy it.

The correlation of Novocure is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Novocure moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Novocure moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Novocure can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Novocure Stock Analysis

When running Novocure's price analysis, check to measure Novocure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novocure is operating at the current time. Most of Novocure's value examination focuses on studying past and present price action to predict the probability of Novocure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novocure's price. Additionally, you may evaluate how the addition of Novocure to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC